FDA Warning Letter Explorer
Drugs · Letter issue date: Apr 11, 2022

Brigham and Women’s Hospital Inc.

4 extracted findings · 3 model-assigned issue types

FDA source excerpt, selected passage

You manufacture PET drug products for parenteral administration in a facility that is not adequately designed or controlled for aseptic processing. In addition, you did not ensure that your equipment is suitable for aseptic operations.

FDA published a close-out letter on May 31, 2023. The findings below are from the original warning letter.

Findings and supporting evidence

Model-assisted readings, not an exhaustive interpretation. Compare with the extracted source findings below.

Facilities & equipment21 CFR 212.30(a)

Facility not adequately designed or controlled for aseptic processing, with water infiltrations and fungal contamination in ISO 5 areas.

Supporting FDA text
Source excerpt · automated text-match check

You manufacture PET drug products for parenteral administration in a facility that is not adequately designed or controlled for aseptic processing. In addition, you did not ensure that your equipment is suitable for aseptic operations.

Sterility & aseptic processing21 CFR 212.30(a)

Environmental monitoring recovered microorganisms in ISO 5 areas, and operators failed to follow disinfection procedures and media fill qualifications.

Supporting FDA text
Source excerpt · automated text-match check

From June 29, 2020 to November 25, 2020, your EM program repeatedly recovered microorganisms, including several fungal organisms, from your facility’s ISO 5 areas. Air monitoring in critical areas should normally yield no microbiological contamination. Your EM program also recovered many of the same organisms in the adjacent ISO 7 areas. During this time, you manufactured drug products including (b)(4) batches of [18F]-Fludeoxyglucose for Injection and (b)(4) sub-batches of [13N]-Ammonia for Injection. You acknowledged in your response that you failed to apply the appropriate minimum contact time for a sporicidal disinfectant used within the ISO 5 area of your biological safety cabinets and hot cells. Additionally, we observed an operator insert their upper torso and head into your biological safety cabinet while performing the cleaning and disinfection process. Furthermore, you failed to ensure all operators completed their media fill qualifications within your established requalification periods, which is a repeat issue from your 2019 inspection. Finally, you failed to adequately follow your procedures to investigate each ISO 5 EM result exceeding action level to determine product impact, identify root causes, and to implement effective corrective actions and preventive actions (CAPA).

Investigations & OOS21 CFR 212.20(d)

OOS endotoxin result for [13N]-Ammonia batch was invalidated without adequate investigation and batch released.

Supporting FDA text
Source excerpt · automated text-match check

For example, analysis of drug product [13N]-Ammonia for Injection, batch 13NNH3210511-A revealed an OOS result for endotoxins, and the batch was released without an adequate investigation. An initial OOS test result was invalidated due to a system suitability failure. A second analysis, which met system suitability criteria, obtained an OOS result of 30.7 EU/mL (exceeding your (b)(4) EU/mL specification). You resampled from the final product vial and conducted another test, which met the specification. You repeated the analysis, which also yielded a passing result. You released the batch and subsequent sub-batches based on the passing results.

Findings extracted from the letter

Selected FDA passages, not the complete letter.

01
You failed to provide adequate facilities for the prevention of contamination.
02
Your firm failed to conduct adequate investigations and take appropriate corrective action when a failure of a production batch or any component of the batch failed to meet any of its specifications. (21 CFR 212.20(d)).
03
You failed to conduct adequate investigations into multiple out-of-specification (OOS) endotoxin results, including implementing appropriate and effective CAPAs.
04
Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.

What FDA requested

Model-assisted summary. Consult the letter for complete requests and conditions.

  • Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to: All human interactions within ISO 5 areas; Equipment placement and ergonomics; Air quality in ISO 5 areas and the surrounding areas; Facility layout; Personnel Flows and Material Flows (throughout all rooms used to support sterile operations); Facility management systems and environmental controls (e.g., temperature, humidity, air handling, interactions of areas of differing classifications)
  • A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment, including specific tangible improvements to be made to aseptic processing operation design, control, and maintenance
  • Your plans and results evaluating whether an adequate state of control was maintained for PET drug production during your facility remediation activities
  • A list of all environmental monitoring results outside alert and action limits for ISO 5 and ISO 7 areas since November 2020
  • Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment, including prompt detection of equipment/facilities performance issues, timely upgrades, adherence to preventive maintenance schedules, effective execution of repairs, and improved systems for ongoing management review
  • Your procedures for conducting routine facility walkthroughs, at appropriate frequencies, to assess the state of repair of your facility in order to mitigate contamination hazards
  • Evaluation whether cleaning and disinfecting methods (e.g., agents, procedures, frequency) used in all classified areas are effective
  • Your facility qualifications, media fills, and most recent static and dynamic smoke studies performed for both the biological safety cabinet and laminar flow hood during and since completion of the facility remediation

Sections and clauses cited

As cited in this historical letter, not a statement of current regulatory requirements.

Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.